by the National Prostatic Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m2 iv every three weeks, or cyclophosphamide 1 g/m2 iv every three weeks plus es
โฆ LIBER โฆ
Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer
โ Scribed by Dr. Hamid Al-Mondhiry; Andrea Manni; John Owen; Robert Gordon
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 518 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Treatment of newly diagnosed metastatic
โ
Gerald P. Murphy; Sunmolu Beckley; Mark F. Brady; T. Ming Chu; Jean B. Dekernion
๐
Article
๐
1983
๐
John Wiley and Sons
๐
English
โ 699 KB
Leukoerythroblastic anemia in metastatic
โ
Glenn J. Shamdas; Frederick R. Ahmann; Monika B. Matzner; Justine M. Ritchie
๐
Article
๐
1993
๐
John Wiley and Sons
๐
English
โ 633 KB
The use of flutamide in hormone-refracto
โ
D. G. McLeod; R. C. Benson Jr; M. A. Eisenberger; E. D. Crawford; B. A. Blumenst
๐
Article
๐
1993
๐
John Wiley and Sons
๐
English
โ 444 KB
๐ 2 views
Prognostic significance of bone metastas
โ
Kazuo Yamashita; Kakuro Denno; Takafumi Ueda; Yoshio Komatsubara; Toshihiko Kota
๐
Article
๐
1993
๐
John Wiley and Sons
๐
English
โ 566 KB
A phase I study of the somatostatin anal
โ
William D. Figg; Alain Thibault; Michael R. Cooper; Robert Reid; Donna Headlee;
๐
Article
๐
1995
๐
John Wiley and Sons
๐
English
โ 578 KB
Circulating levels of interleukin-6 in p
โ
Drachenberg, Darrel E.; Elgamal, Abdel-Aziz A.; Rowbotham, Ron; Peterson, Mary;
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 191 KB
๐ 2 views
BACKGROUND. ) is a cytokine that plays a central role in host defense due to its wide range of immune and hematopoietic activities. It is found in high levels in human ejaculate, and has recently been found to regulate prostate-specific protein expression in prostate cancer cells through nonsteroida